---
title: "Arvind Remedies Ltd (ARVINDREM) — Share Price, Financials & Analysis"
symbol: "ARVINDREM"
company: "Arvind Remedies Ltd"
canonical: "https://tapetide.com/stocks/ARVINDREM"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:51:31.674Z"
---

# Arvind Remedies Ltd (ARVINDREM)

Canonical page: https://tapetide.com/stocks/ARVINDREM

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** arvindremedies.com

## About

Arvind Remedies (ARL) engages in the drugs and pharmaceuticals business of India that manufactures capsules, liquids, ointments, tablets Syrup, Cream & Powders as well as Ayurvedic products at Kancheepuram in Tamilnadu.

## Latest Price

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of -6.73% over last 3 years.
- Company has high debtors of 221 days.
- Company's cost of borrowing seems high

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 32% | — | — |
| revenue growth | -98% | 22% | 21% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 220 | 233 | 274 | 259 | 293 | 176 | 47 | 12 | 6 | 2 | 2 | 1 |
| Expenses | 182 | 187 | 222 | 195 | 251 | 197 | 172 | 14 | 6 | 2 | 98 | 2 |
| Operating Profit | 38 | 46 | 53 | 63 | 42 | -21 | -126 | -2 | 1 | 0 | -95 | 0 |
| OPM % | 17 | 20 | 19 | 25 | 14 | -12 | -269 | -14 | 10 | 1 | -3881 | -21 |
| Other Income | 0 | 0 | 0 | 0 | 0 | -115 | -67 | 0 | 0 | 0 | 4 | -20 |
| Interest | 17 | 18 | 26 | 24 | 33 | 22 | -5 | -4 | 1 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 4 | 7 | 6 | 7 | 4 | 6 | 6 | 1 | 7 | 6 |
| Profit before tax | 18 | 25 | 23 | 33 | 2 | -165 | -191 | -4 | -6 | -2 | -99 | -26 |
| Tax % | 26 | 24 | 53 | 20 | 40 | 0 | -3 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 13 | 19 | 11 | 26 | 1 | -165 | -185 | -4 | -6 | -2 | -99 | -26 |
| EPS in Rs | 1.93 | 2.73 | 1.56 | 3.83 | 0.19 | -24.18 | -27.19 | -0.62 | -0.89 | -0.22 | -14.55 | -3.82 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 15m | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 157 | 176 | 218 | 298 | 363 | 437 | 664 | 911 | 787 | 12 |
| Expenses | 143 | 160 | 198 | 267 | 321 | 369 | 531 | 734 | 842 | 107 |
| Operating Profit | 14 | 16 | 20 | 31 | 41 | 68 | 134 | 177 | -55 | -95 |
| OPM % | 9 | 9 | 9 | 10 | 11 | 16 | 20 | 19 | -7 | -777 |
| Other Income | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | -170 | -16 |
| Interest | 7 | 7 | 11 | 14 | 16 | 28 | 59 | 77 | 71 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 3 | 13 | 14 | 29 | 20 |
| Profit before tax | 5 | 7 | 7 | 15 | 23 | 37 | 63 | 86 | -325 | -133 |
| Tax % | 20 | 26 | 33 | 31 | 26 | 48 | 35 | 32 | -2 | — |
| Net Profit | 4 | 5 | 5 | 11 | 17 | 19 | 41 | 59 | -320 | -133 |
| EPS in Rs | — | — | — | — | 0.35 | 0.4 | 0.84 | 8.65 | -46.98 | -19.48 |
| Dividend Payout % | 30 | 25 | 27 | 12 | 20 | 17 | 12 | 9 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 26 | 26 | 26 | 26 | 26 | 48 | 48 | 48 | 68 | 68 |
| Reserves | 12 | 15 | 19 | 22 | 69 | 73 | 95 | 146 | 211 | -110 |
| Borrowings | 57 | 85 | 86 | 104 | 123 | 184 | 362 | 520 | 623 | 750 |
| Other Liabilities | 22 | 31 | 42 | 40 | 50 | 65 | 98 | 128 | 189 | 77 |
| Total Liabilities | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1092 | 784 |
| Fixed Assets | 26 | 29 | 30 | 35 | 36 | 45 | 242 | 251 | 349 | 275 |
| CWIP | 5 | 27 | 35 | 20 | 38 | 19 | 49 | 37 | 67 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 6 | 3 |
| Other Assets | 86 | 102 | 108 | 138 | 194 | 306 | 309 | 551 | 670 | 505 |
| Total Assets | 117 | 158 | 173 | 192 | 268 | 370 | 603 | 842 | 1092 | 784 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -9 | 10 | 16 | -13 | -8 | 12 | 7 | 13 | -60 | -151 |
| Cash from Investing Activity | -7 | -27 | -12 | 8 | -21 | -62 | -158 | -123 | -21 | 105 |
| Cash from Financing Activity | 7 | 20 | -8 | 5 | 42 | 55 | 152 | 112 | 63 | 44 |
| Net Cash Flow | -9 | 4 | -3 | 0 | 13 | 6 | 1 | 2 | -18 | -2 |
| Free Cash Flow | -16 | -16 | 4 | -5 | -29 | -50 | -149 | -108 | -79 | -39 |
| CFO/OP | -76 | 80 | 107 | -60 | -18 | 46 | 19 | 19 | -31 | 276 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Jun 2015 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 135 | 152 | 143 | 140 | 131 | 135 | 142 | 133 | 133 | 221 |
| Inventory Days | 66 | 75 | 78 | 65 | 66 | 68 | 92 | 89 | 104 | 3 |
| Days Payable | 23 | 47 | 69 | 50 | 48 | 49 | 40 | 49 | 50 | 4 |
| Cash Conversion Cycle | 178 | 179 | 152 | 155 | 149 | 155 | 194 | 173 | 187 | 221 |
| Working Capital Days | 178 | 170 | 149 | 176 | 171 | 162 | 174 | 177 | 206 | 214 |
| ROCE % | — | 11 | 11 | 13 | 16 | 15 | 16 | 20 | 20 | -9 |

## Shareholding Pattern

### annual

| Category | Mar 2016 | Jun 2016 |
| --- | --- | --- |
| Promoters | 3.58% | 3.58% |
| DIIs | 0.02% | 0.02% |
| Public | 96.41% | 96.41% |
| No. of Shareholders | 71277 | 71277 |

### Quarterly

| Category | Mar 2016 | Jun 2016 |
| --- | --- | --- |
| Promoters | 3.58% | 3.58% |
| DIIs | 0.02% | 0.02% |
| Public | 96.41% | 96.41% |
| No. of Shareholders | 71277 | 71277 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Of Newspaper Advertisement for the dispatch of Postal Ballot Notice. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 9h - Of Newspaper Advertisement for the dispatch of Postal Ballot Notice.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2a9e9320-4f27-4544-a669-01daf501e928.pdf) |
| 9 Feb - Newspaper Publication of Financial Results for quarter and nine months ended December 31, 2025. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Feb - Newspaper Publication of Financial Results for quarter and nine months ended December 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/30b90500-35a9-4335-a89c-df8bb16b5744.pdf) |
| 6 Feb - Audio of Feb 6, 2026 investor conference call for Q3/9M FY26 results uploaded; transcript to follow. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 6 Feb - Audio of Feb 6, 2026 investor conference call for Q3/9M FY26 results uploaded; transcript to follow.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/10e7053a-9d0a-4f41-b0c5-fc4fc70547e8.pdf) |
| 6 Feb - Approved Q3/9M results; EUR 3M equity infusion to Singapore subsidiary; independent director change Feb 06, 2026. | [Announcement Of Equity Infusion In Our Wholly Owned Subsidiary Based In Singapore 6 Feb - Approved Q3/9M results; EUR 3M equity infusion to Singapore subsidiary; independent director change Feb 06, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/539f86a8-9b51-4919-a05c-e65ef612ac73.pdf) |
| 11 Feb - Of Transcript of Earnings Conference Call for the quarter and nine months ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 11 Feb - Of Transcript of Earnings Conference Call for the quarter and nine months ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b2023480-aade-47e2-8e27-57faea1441bc.pdf) |
| 10 Feb - Investor/analyst meeting on Feb 16, 2026 hosted by Spark Capital; in-person in Mumbai. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Feb - Investor/analyst meeting on Feb 16, 2026 hosted by Spark Capital; in-person in Mumbai.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/041c22d4-d37c-42d1-968d-f2a257715b16.pdf) |
| — | [Limited Review Report for June 30, 2016 13 Aug 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72113465_91B3_4542_A5E5_D509C98F7963_142355.pdf) |
| — | [Limited Review Report for June 30, 2016 13 Aug 2016](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2016/8/72113465_91B3_4542_A5E5_D509C98F7963_142355.pdf) |
| — | [Standalone Financial Results for June 30, 2016 12 Aug 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=800BCE28_1F53_4467_838D_5E619767D55C_192602.pdf) |
| — | [Outcome of Board Meeting 12 Aug 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60560B63_4D63_4E74_9EDA_9E9CB9C2D209_193002.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/927053e1-abcc-48ca-9c75-df3aaed2c2c1.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ab8d723f-004b-4c12-be45-5c99c92f1b3e.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3c2c626b-174e-40cb-a075-aaf71b35094a.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/05007266-d6dc-41e4-8f71-cc94ea1090ba.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ab048eea-86e3-40ac-a321-cd07eca3c140.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5477829b-0ba6-4818-81e6-cb52cbe31e8c.pdf) |
| Jun 2023 | [Concall - Jun 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ff120fa4-67e3-4ba6-bc89-18a86c8db094.pdf) |
| Jun 2022 | [Concall - Jun 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc30db75-fb83-4fa6-8a27-9dd0bd2f885e.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8164a24b-aa8c-4d4c-a19d-1edefb8be03b.pdf) |
| Feb 2024 | [Concall - Feb 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/781a9721-3ca6-41c7-8a92-02d81c0aa48e.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3d4ccced-602f-4041-9be6-e2e2af083d8c.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/69dc755e-f2a4-4d7f-b4b4-94644bead1f9.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a99d6e9b-d660-4555-979d-40faa637f646.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/543399/73471543399_08_07_22.pdf) |
| from bse | [Annual Report 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230315.pdf) |
| from bse | [Annual Report 2014 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230314.pdf) |
| from bse | [Annual Report 2013 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230313.pdf) |
| from bse | [Annual Report 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230312.pdf) |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport/531823/5318230310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:51:31.674Z.